BioMarin seeks label expansion for achondroplasia drug; FDA lifts Inhibikase full clinical hold
BioMarin is looking to press its advantage in the achondroplasia, or dwarfism, drug space.
The California company said Tuesday afternoon the FDA
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
